mics against e coli atcc 25922  (ATCC)

Journal: RSC Advances

Article Title: Synthesis and antibacterial activity study of anti-biofilm agents based on American oyster defensin analog A4

doi: 10.1039/d6ra02550a

Figure Lengend Snippet: Effect of D-A4 and A4-T3 on the membrane permeabilization of E. coli ATCC 25922.

Article Snippet: The serum stability of D-A4 and A4-T3 was assessed by measuring their MICs against E. coli ATCC 25922 in the presence of varying concentrations of fetal bovine serum.

Techniques: Membrane

Journal: RSC Advances

Article Title: Synthesis and antibacterial activity study of anti-biofilm agents based on American oyster defensin analog A4

doi: 10.1039/d6ra02550a

Figure Lengend Snippet: Time-kill curve of D-A4 and A4-T3 against E. coli ATCC 25922.

Article Snippet: The serum stability of D-A4 and A4-T3 was assessed by measuring their MICs against E. coli ATCC 25922 in the presence of varying concentrations of fetal bovine serum.

Techniques:

Journal: bioRxiv

Article Title: Nutrient-limited conditions reveal the activity of a minor groove binder, MGB-BP-3, against Escherichia coli

doi: 10.64898/2025.12.22.695926

Figure Lengend Snippet:

Article Snippet: The promising MIC against E. coli ATCC 25922 prompted us to assess MGB-BP-3 against a small panel of multi-drug-resistant clinical isolates ( ).

Techniques:

Journal: bioRxiv

Article Title: Nutrient-limited conditions reveal the activity of a minor groove binder, MGB-BP-3, against Escherichia coli

doi: 10.64898/2025.12.22.695926

Figure Lengend Snippet: Effect of calcium (Ca 2+ ), magnesium (Mg 2+ ) and ferrous (Fe 2+ ) concentrations on the antibacterial activity of MGB-BP-3 against E. coli ATCC 25922 in RPMI+10%LB. Increasing cation concentrations to 0.8 mM, 1.6 mM, and 3.2 mM resulted in higher MIC values, indicating reduced antibacterial activity of MGB-BP-3.

Article Snippet: The promising MIC against E. coli ATCC 25922 prompted us to assess MGB-BP-3 against a small panel of multi-drug-resistant clinical isolates ( ).

Techniques: Activity Assay

Journal: bioRxiv

Article Title: Nutrient-limited conditions reveal the activity of a minor groove binder, MGB-BP-3, against Escherichia coli

doi: 10.64898/2025.12.22.695926

Figure Lengend Snippet: Viable counts for cultures of E. coli 25922. Results are shown as No treatment control and cultures treated at 35±2° C for 24 hours, with MGB-BP-3 concentration corresponding to 0.5, 1, 5 and 10 times the MIC value determined.

Article Snippet: The promising MIC against E. coli ATCC 25922 prompted us to assess MGB-BP-3 against a small panel of multi-drug-resistant clinical isolates ( ).

Techniques: Control, Concentration Assay

Journal: bioRxiv

Article Title: Nutrient-limited conditions reveal the activity of a minor groove binder, MGB-BP-3, against Escherichia coli

doi: 10.64898/2025.12.22.695926

Figure Lengend Snippet: (a) Toxicity effects of MGB-BP-3 on G. mellonella larvae at various concentrations, monitored over 5 days. (b) Survival probability of G. mellonella larvae after 5 days of treatment with MGB-BP-3 following infection with 5×10 6 CFU/mL of E. coli ATCC 25922 strain. (c) Survival probability of G. mellonella larvae after 5 days of treatment with MGB-BP-3 following infection with 5×10 8 CFU/mL of S. aureus. Larvae were administered either PBS (control-treated) or MGB-BP-3 at various doses and incubated at 37°C. A single dose of the MGB-BP-3 treatment was given 2 hours post-infection. The number of surviving larvae was recorded every day for a total of 5 days. The uninfected PBS/PBS group represents larvae that were sham injected with sterile PBS (to serve as a control for the physical injection) and subsequently treated with sterile PBS. Statistical analyses were conducted using the log-rank test, with a significance level set at (p < 0.05) for multiple comparisons. All experiments were performed in triplicate, with a sample size of (n = 30)

Article Snippet: The promising MIC against E. coli ATCC 25922 prompted us to assess MGB-BP-3 against a small panel of multi-drug-resistant clinical isolates ( ).

Techniques: Infection, Control, Incubation, Injection, Sterility